Article suivant

The US Congress introduces a package of bills seeking changes to antitrust and patent law in the pharmaceutical industry

The pharmaceutical industry, like the technology sector, has become as a focus of U.S. lawmakers seeking to revise competition law. In April 2021, House and Senate lawmakers introduced a package of legislation targeting conduct that supposedly prevents or slows competition from less expensive drugs. Three bills propose antitrust changes targeting so-called "reverse payment" patent settlements, "product hopping," and "sham" citizen petitioning. The presumptions created by these bills would increase the risk associated with licensing and other business arrangements between parties settling patent cases, as well as with launching newer versions of existing drugs and petitioning the FDA. The fourth bill caps the number of patents in an infringement action resulting from the "patent

L'accès à cet article est réservé aux abonnés

Déjà abonné ? Identifiez-vous

L’accès à cet article est réservé aux abonnés.

Lire gratuitement un article

Vous pouvez lire cet article gratuitement en vous inscrivant.

 

Version PDF

Auteurs

  • White & Case (New York)
  • White & Case (New York)
  • White & Case (New York)

Citation

Michael Gallagher, Kevin Adam, Ada Yue Wang, The US Congress introduces a package of bills seeking changes to antitrust and patent law in the pharmaceutical industry, 21 avril 2021, e-Competitions November 2021 - II, Art. N° 101413

Visites 128

Tous les numéros

  • Latest News issue 
  • Tous les News issues
  • Latest Special issue 
  • Tous les Special issues